this was an area previously [where] this particular tumor has been one that has been really quite resistant to immunotherapy. There was excitement with regard to that particular program. And it may be in certain ways the lenvatinib is very important with the pembrolizumab for the chr...
Despite the unprecedented virtual nature of its pro-gram, this year's American Society of Clinical On-cology (ASCO) fulfilled its promise of offering a"diverse program, a multidisciplinary perspective, and awealth of new research, and limitless opportunities fordiscovery" as thousands of oncologists...
Casdatifan Shows Promise in Treating Clear Cell Renal Cell Carcinoma Benjamin Saylor February 21st 2025 Article Casdatifan, a HIF-2α inhibitor, shows early clinical activity and good tolerance in patients with previously treated clear cell renal cell carcinoma. Read More Beyond the First-Line...
I will talk about how we integrate surgery into systemic treatment in 2012, the role of cytoreductive surgery, and then introduce the idea of pre-surgical therapy, something that we have been studying here at MD Anderson that has shown some promise. These are two randomized trials, one in th...
Lenvatinib (Lenvima, Eisai) plus pembrolizumab (Keytruda, Merck) showed significant response rates in unresectable hepatocellular carcinoma and in patients with metastatic clear cell renal cell carcinoma who progressed following immune checkpoint inhibit
Our Promise Genentech's legacy and future aspirations are built on the belief that the boundaries of science are meant to be broken and that we can solve some of the hardest biomedical challenges plaguing humankind. Learn More Quick Links Advancing Inclusive Research Patient Financial Support ...
The data have led us to preliminarily conclude that dual targeting of HIF-2α and VEGF pathways may be an effective treatment strategy in advanced clear cell RCC,” presenter Jaime R. Merchan, MD, director, Phase I Program, University of Miami Sylvester Comprehensive Cancer Center, Florida, sa...